Net Zero High confidence
Healthcare
Orphalan UK
United Kingdom and European markets
Company profile
About the company
Orphalan develops and commercialises medicines for rare diseases. Its teams work with clinicians, healthcare systems and patient communities to provide treatments in specialist therapeutic areas. The UK operation forms part of a European pharmaceutical business and relies on third-party suppliers for many operational activities.
Public claim
What the listing records.
“Orphalan UK commits to achieving net-zero emissions by 2045.”
Evidence note
The signed March 2024 plan identifies Orphalan UK as a small company, states the 2045 target and reports a 27.932 tCO2e 2023 baseline.
Source type: Public report